GI Oncology
From the Journals
S-1 regimen noninferior to other frontline mCRC options
Frontline treatment with the oral fluoropyrimidine S-1 combined with irinotecan and bevacizumab was noninferior to other common regimens.
From the Journals
Study: Test carcinoembryonic antigen in colon cancer after surgery
Researchers suggest that a recommended preoperative measurement actually provides more predictive value postoperatively.
From the Journals
Tc-325 effective for immediate GI tumor bleeding
This powder seems to be more predictably effective in providing initial hemostasis in upper GI tumor bleeding, compared with conventional methods...
From the Journals
Refractory FGFR-altered cholangiocarcinoma responds to FGFR kinase inhibitor
A median progression-free survival of 5.8 months is encouraging in patients with this aggressive cancer, and this targeted therapy warrants...
From the Journals
Mutations influence prognostic value of tumor location in stage III colon cancer
In patients with BRAF or RAS mutations, DFS was better in right-sided vs. left-sided tumors, while in patients with RAS and BRAF double wild type...
From the Journals
MMR deficiency testing remains low in colorectal cancer patients
Utilization of mismatch repair deficiency testing is poor among patients with colorectal cancer, and remains particularly low among young adults...
Conference Coverage
Nivolumab may extend survival in HCC patients
WASHINGTON – About 20% of patients achieved an objective remission that included complete responses in all subgroups of patients.
From the Journals
Survey colonoscopy outpatients to flag high cancer risk
Paper and electronic surveys together identified patients in need of referral for genetic testing for colorectal cancer risk.
News
FDA approves pembrolizumab for gastric and GEJ adenocarcinoma
The checkpoint inhibitor is approved for patients with advanced tumors containing PD-L1 and where the disease is progressing on or after two or...
From the Journals
Study shows childhood IBD increased cancer risk in adulthood
Childhood inflammatory bowel disease was associated with significant increases in the risk of cancer in later life.
From the Journals
Consider adding chemotherapy after GI surgery
Average survival rates at 3 years after surgery were 40 months for those who received adjuvant chemotherapy vs. 34 months for those who did not....